Articles

The debate looked at establishing partnership accountability and transparency and the big question was - Who is accountable for over runs and the true cost association of delaying time to market? Read more

How many times have you heard in your organisation:‘oh you can’t do that here, it’s impossible.’ Perhaps it’s something you’ve quietly thought yourself. While change is very often a great thing, bringing more good than bad to an organisation, many of us look at it as a time-consuming upheaval to our daily working lives and prefer to recoil into the comfortable space of the familiar. Pharma IQ has put the feelers out into the Biotech community and come up with some Top Tips which will help make what appears impossible in your organisation, possible Read more

"This year I am excited to be attending the conference as the topics are current and the case studies, solutions discussed, and tools to use will be of tremendous value to myself and all the attendees," said Steve Jacobs, Chair of the Global Clinical Supplies Group. Read more

It is clear some work has begun to increase the number of clinical trials in Norway, Sweden, Denmark, Finland and Iceland. Read more

According to a recent Pharma IQ survey, 43 per cent of Pharma professionals do not think the oversight of their clinical trial vendors is effective and 100 per cent claimed that the increasing levels of regulatory scrutiny are adding unnecessary pressure. Read more

However, it is not just regulations that can drive up the cost of drug development and, eventually, distribution, some practitioners are calling for even more testing prior to approval, to ensure that drugs are actually cost effective to use – particularly with rare drugs and in countries with no public health care system. Read more

As a member of the global clinical development community, we are asking for your perceptions and experiences of selecting and working with CROs and other clinical partners. We’d really appreciate your contribution to the biggest survey of its kind. Please take the time to complete it and we’ll send you the results first! Read more

Survey respondents indicated that their company is planning on outsourcing an average of 4.38 different services in the coming year. Those from emerging biotech / biologics demonstrated the strongest numbers, indicating that they would outsource an average of 5.52 services – making them strong candidates for CROs and CMOs with appropriate capabilities to target. Read more

In particular the treatment was found to be particularly effective on one set of patients with a certain number of lymphocytes, suggesting these could be used as a biomarker to determine who would benefit from immunotherapy. Read more

Can confidence in European research be restored via some simple solutions at the National level? Is there something pragmatic which can be dealt with at the Site level? Or are there more complex issues to be addressed? We would encourage you to complete this survey (approx. 10 min) to add your perspective to this question. Read more

Large patient pools and lower costs are just two of the enticing advantages of conducting clinical trials in Asia. Yet for many in the industry, the inner workings of the Asian market – and indeed the varied markets included under the huge banner – remain a relative mystery. Read more